Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Amortization of Deferred Charges (2021 - 2023)

Historic Amortization of Deferred Charges for GeneDx Holdings (WGS) over the last 3 years, with Q3 2023 value amounting to $130000.0.

  • GeneDx Holdings' Amortization of Deferred Charges changed 0.0% to $130000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $518000.0, marking a year-over-year increase of 1434.88%. This contributed to the annual value of $518000.0 for FY2022, which is 68484.85% up from last year.
  • Per GeneDx Holdings' latest filing, its Amortization of Deferred Charges stood at $130000.0 for Q3 2023, which was down 0.0% from $129000.0 recorded in Q2 2023.
  • In the past 5 years, GeneDx Holdings' Amortization of Deferred Charges registered a high of $131000.0 during Q4 2022, and its lowest value of $66000.0 during Q4 2021.
  • Over the past 3 years, GeneDx Holdings' median Amortization of Deferred Charges value was $129000.0 (recorded in 2022), while the average stood at $121375.0.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first soared by 9848.48% in 2022, then changed by 0.0% in 2023.
  • Over the past 3 years, GeneDx Holdings' Amortization of Deferred Charges (Quarter) stood at $66000.0 in 2021, then surged by 98.48% to $131000.0 in 2022, then fell by 0.76% to $130000.0 in 2023.
  • Its Amortization of Deferred Charges stands at $130000.0 for Q3 2023, versus $129000.0 for Q2 2023 and $128000.0 for Q1 2023.